secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001628280-22-029232
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q3 revenue $57.5M (+33% YoY); net loss widens to $161.2M on Seagen payment
--------------------------------------------------------------------------------

- Total revenues $57.5M vs $43.1M YoY; net product revenue led by ZEJULA $39.2M.
- Net loss $161.2M vs $96.4M YoY, reflecting $30M upfront to Seagen and $36.7M FX loss.
- Cash & equivalents $1.12B; company expects runway through 2025.
- Entered collaboration with Seagen for TIVDAK in Greater China.
- Appointed Dr. Peter Huang as CSO and Alette Verbeek as SVP Global Strategic Partnering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828022029232/0001628280-22-029232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828022029232/zlab-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-029232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer